目的 探讨硫酸氢氯吡格雷对急性冠脉综合征(ACS)患者的抗血小板和抗炎效果.方法 将86例ACS患者分为观察组与对照组,每组各43例.两组均以ACS治疗指南为基础方案,对照组予以阿司匹林,观察组予以硫酸氢氯吡格雷和阿司匹林,均治疗30 d,均于用药前,用药7、30 d后检测患者血超敏C反应蛋白(hs-CRP)及肿瘤坏死因子α(TNF-α)水平.结果 治疗前两组患者hs-CRP与TNF-α水平比较,差异均无统计学意义(P ＞ 0.05);观察组治疗7、30 d后,hs-CRP与TNF-α水平均降低(P ＜ 0.05或P ＜ 0.01);对照组治疗30 d后,hs-CRP与TNF-α水平均降低(P ＜ 0.05);治疗7、30 d后,观察组hs-CRP与TNF-α水平均低于对照组相应时点的水平(P ＜ 0.05).结论 硫酸氢氯吡格雷降低了ACS患者的血hs-CRP及TNF-α水平,具有较好的抗血小板和抗炎作用.%Objective To explore Clopidogrel Sulfate's effect of anti-platelet and anti-inflammatory in patients with a-cute coronary syndrome (ACS). Methods 86 patients with ACS were divided into observation group and control group, with 43 cases in each group. Basic scheme referring to ACS treatment guidelines was used in all patients, and control group was given aspirin, yet observation group was given Clopidogrel Sulfate and Aspirin, and all patients were treated for 30 d. All patients' serum hs-CRP and TNF-a were tested before treatment, 7 d and 30 d after treatment. Results There was no statistical difference on ACS patients serum hs-CRP and TNF-a before treatment (P > 0.05). The serum hs-CRP and TNF-a in observation group both decreased 7 d and 30 d after treatment (P < 0.05 or P < 0.01), and serum hs-CRP and TNF-a in control group decreased 30 d after treatment (P < 0.05), yet serum hs-CRP and TNF-a in observation group were both lower than those of control group in corresponding time of 7 d and 30 d after treatment (P < 0.05). Conclusion Clopidogrel Sulfate decreases ACS patients' serum hs-CRP and TNF-a levels, and it has good anti-platelet and anti-inflammatory effect.
展开▼
